Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 1Phase 2 1

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Adenocarcinoma 7Neoplasms 6Stomach Neoplasms 5Solid Tumors 2Pancreatic Neoplasms 1Metastatic Pancreatic Adenocarcinoma 1Esophageal Neoplasms 1CLDN18.2-positive Gastric Adenocarcinoma 1CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1Adenocarcinoma Of Esophagus 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × zolbetuximab × Clear all
NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Recruiting
2,130 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03504397 2026-05-04

Spotlight

Astellas Pharma Inc

Phase 3 Active not recruiting
565 enrolled 63 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03653507 2026-04-17

GLOW

Astellas Pharma Inc

Phase 3 Active not recruiting
507 enrolled 65 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT03505320 2026-04-03

ILUSTRO

Astellas Pharma Inc

Phase 2 Active not recruiting
143 enrolled
Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT03528629 2024-12-02

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Astellas Pharma Inc

Phase NA Completed
18 enrolled
Gastrointestinal

Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡